CN112584834A - 用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物 - Google Patents
用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物 Download PDFInfo
- Publication number
- CN112584834A CN112584834A CN201980050370.7A CN201980050370A CN112584834A CN 112584834 A CN112584834 A CN 112584834A CN 201980050370 A CN201980050370 A CN 201980050370A CN 112584834 A CN112584834 A CN 112584834A
- Authority
- CN
- China
- Prior art keywords
- acid
- compound
- extranodal
- cell lymphoma
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
提供一种用于治疗结外NK/T细胞淋巴瘤的喹啉衍生物。所提供的化合物I或其药学上可接受的盐，可用于治疗门冬酰胺耐药的结外NK/T细胞淋巴瘤患者，尤其对于门冬酰胺耐药的、复发或难治性结外NK/T细胞淋巴瘤患者，疗效评估结果表明其症状得到缓解，其生存期得到延长。
Description
PCT国内申请，说明书已公开。
Claims (10)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810886395 | 2018-08-06 | ||
| CN2018108863958 | 2018-08-06 | ||
| PCT/CN2019/099264 WO2020029918A1 (zh) | 2018-08-06 | 2019-08-05 | 用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112584834A true CN112584834A (zh) | 2021-03-30 |
| CN112584834B CN112584834B (zh) | 2022-04-12 |
Family
ID=69413410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980050370.7A Active CN112584834B (zh) | 2018-08-06 | 2019-08-05 | 用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN112584834B (zh) |
| WO (1) | WO2020029918A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113750096A (zh) * | 2020-06-02 | 2021-12-07 | 正大天晴药业集团股份有限公司 | 用于治疗外周t细胞淋巴瘤的喹啉衍生物 |
| EP4180055A4 (en) * | 2020-08-07 | 2024-01-10 | Cspc Zhongqi Pharmaceutical Tech Shijiazhuang Co Ltd | USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME AND PEGASPARGASE |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102216332A (zh) * | 2008-10-31 | 2011-10-12 | 艾伯特生物治疗学公司 | 抗-cs1抗体用于治疗罕见淋巴瘤的用途 |
| CN103483319A (zh) * | 2007-03-14 | 2014-01-01 | 南京爱德程医药科技有限公司 | 作为血管生成抑制剂的螺取代化合物 |
-
2019
- 2019-08-05 WO PCT/CN2019/099264 patent/WO2020029918A1/zh active Application Filing
- 2019-08-05 CN CN201980050370.7A patent/CN112584834B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103483319A (zh) * | 2007-03-14 | 2014-01-01 | 南京爱德程医药科技有限公司 | 作为血管生成抑制剂的螺取代化合物 |
| CN102216332A (zh) * | 2008-10-31 | 2011-10-12 | 艾伯特生物治疗学公司 | 抗-cs1抗体用于治疗罕见淋巴瘤的用途 |
Non-Patent Citations (3)
| Title |
|---|
| HUANG, YL ET AL.: "Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type", 《BLOOD》 * |
| 金震等: "自分泌PDGF/PDGFR环路对NK/T细胞淋巴瘤细胞增殖的影响及其机制研究", 《白血病 淋巴瘤》 * |
| 黄小银: "NK/T细胞淋巴瘤发病机制研究进展", 《中国肿瘤临床》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112584834B (zh) | 2022-04-12 |
| WO2020029918A1 (zh) | 2020-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107001326B (zh) | 抗非小细胞肺癌的喹啉衍生物 | |
| EP1962839A2 (en) | Administration of mntor inhibitor to treat patients with cancer | |
| CN110650741A (zh) | 用于治疗结直肠癌的喹啉衍生物 | |
| CN113710658A (zh) | 用于治疗尤因肉瘤的喹啉类化合物或其药学上可接受的盐 | |
| CN112584834B (zh) | 用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物 | |
| CN115025090A (zh) | 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 | |
| CN116159062A (zh) | 药物组合物及其用途 | |
| US20130101680A1 (en) | Radiotherapy enhancer | |
| US11419862B2 (en) | Quinoline derivative for treatment of nasopharyngeal carcinoma | |
| WO2020057536A1 (zh) | 用于治疗脑肿瘤的喹啉衍生物 | |
| CN111757736B (zh) | 治疗鼻咽癌的喹啉衍生物 | |
| CN106999485B (zh) | 抗肺鳞癌的喹啉衍生物 | |
| CN111757737B (zh) | 用于治疗三阴性乳腺癌的喹啉衍生物 | |
| CN112533600B (zh) | 用于治疗小细胞肺癌的喹啉衍生物 | |
| CN112105361A (zh) | 用于治疗非小细胞肺癌的喹啉衍生物 | |
| CN111110681A (zh) | 喹啉衍生物联合卡培他滨在治疗肝癌的用途 | |
| CN115463143A (zh) | 非天然人参皂苷3β,12β-Di-O-Glc-PPD治疗脑瘤的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |